
In view of the promising developments in preclinical studies on the cryopreservation of human ovarian tissue offering this technology as a 'fertility insurance' to cancer patients can be justified. This commentary briefly discusses some of the ethical issues involved, including the doctors responsibility regarding the risk of the reintroduction of cancer, the pros and cons of both xenotransplantation and in vitro maturation, parental responsibility in consenting to fertility insurance for minors, and cryopreservation of ovarian tissue of younger, healthy women who wish to postpone fertility.

